Is there any place for resistant starch, as alimentary prebiotic, for patients with type 2 diabetes?

Bahram Pourghassem Gargari; Nazli Namazi; Mohammad Khalili; Bahareh Sarmadi; Mohammad Asghari Jafarabadi; Parvin Dehghan

doi:10.1016/j.ctim.2015.09.005

Is there any place for resistant starch, as alimentary prebiotic, for patients with type 2 diabetes?

Complement Ther Med. 2015 Dec;23(6):810-5. doi: 10.1016/j.ctim.2015.09.005. Epub 2015 Sep 16.

Authors

Bahram Pourghassem Gargari¹, Nazli Namazi², Mohammad Khalili³, Bahareh Sarmadi⁴, Mohammad Asghari Jafarabadi⁵, Parvin Dehghan⁶

Affiliations

¹ Department of biochemistry & Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
² Faculty of Nutrition, Nutrition Research Center, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
³ Neurosciences Research Center Tabriz University of Medical Sciences, Tabriz, Iran.
⁴ Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia.
⁵ Traffic Injury Prevention Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
⁶ Faculty of Nutrition, Nutrition Research Center, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: dehghan.nut@gmail.com.

PMID: 26645521
DOI: 10.1016/j.ctim.2015.09.005

Abstract

Objective: The aim of the present study was to determine effects of Resistant Starch (RS2) on metabolic parameters and inflammation in women with type 2 diabetes (T2DM).

Methods: In this randomized controlled clinical trial, 60 females with T2DM were divided into intervention (n = 28) and placebo groups (n = 32). They received 10 g/d RS2 or placebo for 8 weeks, respectively. Fasting blood sugar (FBS), glycated hemoglobin (HbA1c), lipid profile, high-sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were measured at baseline and at the end of the trial. Paired t test, unpaired t-test and ANCOVA were used to compare the quantitative variables. The data were analyzed using SPSS software version 13.0.

Results: RS2 decreased HbA1c (-0.3%, -3.6%), TNF-α (-3.4 pg/mL, -18.9%), triglyceride (-33.4 mg/dL, -15.4%), and it increased HDL-c (+9.4 mg/dL, +24.6%) significantly compared with the placebo group (p < 0.05). Changes in FBS, total cholesterol, low-density lipoprotein, hs-CRP and IL-6 were not significant in the RS2 group compared with the control group. RS2 can improve glycemic status, inflammatory markers and lipid profile in women with T2DM.

Conclusions: Although findings of the present study indicated positive effects of RS2 on inflammation and metabolic parameters, more studies are needed to confirm efficacy of RS2 as an adjunct therapy in diabetes.

Keywords: Inflammation; Lipid profile; Resistant starch; Type 2 diabetes.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Blood Glucose / analysis
C-Reactive Protein / analysis
Diabetes Mellitus, Type 2 / diet therapy*
Female
Glycated Hemoglobin / analysis
Humans
Inflammation / diet therapy*
Iran
Middle Aged
Prebiotics*

Substances

Blood Glucose
Glycated Hemoglobin A
Prebiotics
hemoglobin A1c protein, human
C-Reactive Protein